Psilocybin at the edge of approval — the science, the law, the money, and what comes next. A living record of the most consequential moment in the history of psychedelic medicine.
New here? This is your two-minute primer.
Psilocybin is a naturally occurring psychoactive compound found in 200+ species of fungi — commonly called “magic mushrooms.” When ingested, the body converts it to psilocin, which binds to serotonin receptors in the brain and temporarily disrupts the default mode network — the system linked to rumination and rigid thinking. The result is a 4–6 hour experience that researchers now associate with lasting improvements in depression, addiction, and emotional wellbeing.
It is not addictive, has no known lethal dose, and has been used in indigenous healing traditions for over 3,000 years. Despite this, it has been a federal Schedule I substance since 1970. That classification is now under direct challenge from one of the fastest-growing bodies of evidence in modern psychiatry, a presidential executive order signed April 18, 2026, and two complete New Drug Applications sitting before the FDA as of November 2026.
After decades of prohibition, 102 of the 134+ registered psilocybin trials were started in just the last five years. The human clinical results are remarkable and consistent. The preclinical picture, as of November 2026, is more complicated — and that tension is the most interesting thing happening in the science right now.
| Company | Compound | Indication | Status |
|---|---|---|---|
| Compass Pathways | COMP360 (synthetic) | Treatment-Resistant Depression | NDA COMPLETE Nov 9, 2026 · 30–60 day review |
| Cybin / Helus Pharma | HLP003 (deuterated) | Major Depressive Disorder | BT Designation · Phase 3 underway |
| Usona Institute | Psilocybin (non-profit) | Major Depressive Disorder | NDA FILED Nov 2026 · Priority Voucher held |
| AbbVie / Gilgamesh | Bretisilocin (GM-2505) | MDD | Phase 2 · $1.2B acquisition |
| GH Research | Mebufotenin (5-MeO-DMT) | TRD | Phase 3 planned 2026 · 73% remission |
| Eli Lilly (AtaiBeckley) | BPL-003 (intranasal mebufotenin) | TRD | Phase 2b data Q4 2026 · Acquisition closed Sept 11, 2026 |
| Institution | Focus | Notable |
|---|---|---|
| Johns Hopkins | Depression, addiction, cancer, consciousness | 20+ trials; Center for Psychedelic Research est. 2020; landmark 2006 study that restarted the field worldwide |
| Imperial College London | Brain imaging, depression, mechanisms | World’s first Centre for Psychedelic Research (2019); first modern psilocybin depression trial |
| UCSF Neuroscape | Neuroimaging, neuroplasticity | Psychedelics Division est. 2021; Robin Carhart-Harris directs |
| Yale | Depression, OCD, brain structure | 8 trials; psilocybin causes structural brain changes countering depression |
| Mount Sinai | PTSD, trauma | Centre for Psychedelic Psychotherapy and Trauma Research (2021) |
| VA Palo Alto / Stanford | Veterans with TRD and PTSD | First psilocybin study within the VA system |
| Ohio State | Long-term depression outcomes | 5-year durability follow-up data (2025) |
| Emory University | Anti-aging, longevity, eligibility | 2025 aging study: +50% cell lifespan, +30% mouse survival; 5M+ eligibility estimate |
COMP360 25mg hit its primary endpoint in all three Phase 3 trials (1,000+ patients). COMP005 (June 2025): p<0.001, -3.6 MADRS. COMP006 (Feb 2026): p<0.001, -3.8 MADRS. NDA rolling submission planned Q4 2026.
Compass Pathways IR, 2025–2026
COMP005: 258 patients, 32 U.S. sites, double-blind RCT. DSMB found no unexpected safety signals.
COMP006: Confirmed in a second independent population. Combined 1,000+ participants.
FDA policy: One pivotal trial is now the default standard — both trials exceeded the bar.
Head-to-head trial found psilocybin comparable to escitalopram (leading SSRI) for depression, with advantages on several secondary measures including social functioning and emotional processing.
Two-thirds of participants remained free from depression five years after just two doses of psilocybin with psychotherapy support. Researchers propose the compound triggers lasting “positive behavioral feedback loops.”
A single high dose produced substantial, sustained decreases in depression and anxiety in patients with life-threatening cancer — effects lasting 6+ months. One of the most replicated findings in the field.
80% abstinence at 6 months vs. ~35% for best available treatments. Among the highest cessation rates ever recorded in clinical research. 60% still abstinent at 30 months.
Johnson et al., Johns Hopkins
First-in-kind VA pilot: 60% response, 53% remission at 3 weeks. 47% maintained response at 12 weeks. Co-morbid PTSD did not worsen outcomes.
Ellis et al., J Affective Disorders, 2025
Setting: VA Palo Alto / Stanford. 15 veterans, single 25mg dose, open-label.
12-month follow-up: Durable benefits in a subset. VA announced first-ever psychedelic research funding Jan 2024.
75% of participants achieved full remission at 4 months after just 2 doses. Shorter session duration than standard psilocybin is a practical clinical advantage.
Cybin/Helus Phase 2, 2024
First randomized controlled trial showed significant reductions in heavy drinking days vs. control. Establishes psilocybin as a potential AUD treatment.
Open-label trial: 20 adults with chronic suicidal ideation and treatment-resistant depression received a single 25mg COMP360 dose. Statistically significant reductions in suicidal ideation within one week, sustained through 12 weeks. 70% reported minimal or no ideation by week 12. No serious adverse events. Most psychedelic trials exclude suicidal patients — this study directly addresses that critical gap.
Psilocin extended human skin and lung cell lifespan by 50%+. Aged mice given monthly doses showed a 30% increase in survival, improved fur quality, reduced oxidative stress, improved DNA repair, and preserved telomere length — targeting multiple hallmarks of aging simultaneously.
Kato et al., npj Aging, July 2025
Institutions: Emory University School of Medicine; Baylor College of Medicine.
Lead authors: Kosuke Kato, Louise Hecker, Ali John Zarrabi (Director of Psychedelic Research, Emory).
Cell results: Lung cells: 57% longer to senescence. Skin cells: 51% lifespan increase.
Mouse results: 19-month-old females (~60 human years). 30% survival increase. Healthier fur; regrowth observed.
Key insight: Most body cells express serotonin receptors — psilocybin’s effects may not be limited to the brain.
Quote: “These mice weren’t just surviving longer — they experienced better aging.” — Dr. Zarrabi
The PsiDeR trial — the UK’s first publicly funded randomized psilocybin study — enrolled 60 patients with treatment-resistant depression at South London & Maudsley NHS Trust. At three weeks, 40% of the psilocybin arm were in remission vs. 3% on placebo. Response rates: 43% at week 3, rising to 50% at week 6. Framed as a feasibility study, it established that this model of care can be delivered inside a public health system.
King’s College London / Nature Medicine, August 6, 2026
The question it answers: Every prior trial ran in well-funded private or academic research settings. PsiDeR tested whether a national health service can actually deliver it.
The question it doesn’t: Scalability, cost per patient, and staffing. The accompanying Nature Medicine News & Views piece (Aug 21) identified clinic capacity and trained staff as the scarce inputs — not the drug.
UC Santa Cruz researchers found that serotonin 2A signaling in Layer 5 pyramidal neurons is both necessary and sufficient for psilocybin’s structural neuroplasticity — yet entirely dispensable for its hallucinogenic output. Psilocybin accelerated the formation and maturation of new neural connections while pruning others, and the effect depended on the animal’s prior stress exposure.
Baker & Zuo et al., Nature Neuroscience, October 2026
Senior author: Yi Zuo. Lead author: Jacob Baker (doctoral researcher). DOI: 10.1038/s41593-026-02490-y.
Hallucination proxy: The head-twitch response — the standard rodent measure — was unaffected when those receptors were disabled, while plasticity remained intact.
Why it matters: If therapeutic remodeling and the subjective trip run on genuinely separate cellular pathways, a non-hallucinogenic analog becomes a real engineering target. That would remove the 6–8 hour supervised session — the single largest cost and access barrier in the field.
Caveat: Mice. No non-hallucinogenic human candidate exists yet.
Five labs — at UC Berkeley, UCSF, and Stanford — ran parallel mouse experiments to the same protocol. The result: no replicable effect 24 hours after a single dose, and no antidepressant-like effects observed by any lab or in the pooled analysis. Acute effects did reproduce: anxiety reduction, fear suppression, and head-twitch appeared in all five.
Multi-institutional study, Nature Neuroscience, November 2, 2026
Scope: Mouse behavioral models only. This does not contradict the human Phase 3 data, which rests on 1,000+ patients and three successful trials.
What it does challenge: The preclinical literature used to explain why psilocybin works, and the rodent models used to screen next-generation compounds. Inter-lab differences were not explained by any variable the researchers tested.
Authors’ framing: Stephan Lammel and Andrea Gomez (Berkeley) suggest the field refocus on reproducible acute effects and deemphasize findings that do not replicate.
Honest read: Psilocybin’s clinical case is built on human outcomes, not mouse mechanism. But a shaky preclinical foundation makes the next decade of analog development harder, and this paper is a genuine corrective to a field that has been short on negative results. DOI: 10.1038/s41593-026-02500-z.
Two complete NDAs now sit before the FDA with a 30–60 day review target. Three states legal, five with trigger laws ready to fire on approval, fifteen-plus cities decriminalized. The path is no longer a schedule — it is a countdown.
Compass Pathways has finished submitting its New Drug Application for COMP360 psilocybin in treatment-resistant depression — the first complete psilocybin NDA in history. The filing rests on Phase 3 COMP005, Phase 3 COMP006, and a Phase 2b study, each of which met its primary endpoint, across 1,000+ participants. Because Compass holds a Commissioner’s National Priority Voucher, the FDA review target is 30–60 days from completion — putting a decision in play before the end of 2026 or in very early 2027. Commercial launch is anticipated in H1 2027, subject to approval and DEA rescheduling.
The review: A National Priority Voucher compresses review to 1–2 months, but the FDA can still issue a Complete Response Letter, request more data, or impose REMS conditions that delay launch.
The REMS question: Both Compass and Usona are reportedly working with the agency on Risk Evaluation and Mitigation Strategy design. A restrictive REMS — certified prescribers, registered facilities, mandatory monitoring windows — shapes how accessible the drug actually is on day one.
The DEA step: Approval alone does not permit dispensing. Rescheduling can only begin after a specific product is approved, and the most likely outcome is formulation-specific rescheduling: COMP360 moves out of Schedule I while psilocybin as a substance stays put. Estimates for this step range from ~90 days to the historical 12–18 months.
Sources: Compass Pathways IR · Psychiatric Times · Drug Discovery Trends
In a development few predicted, the non-profit Usona Institute has also completed an NDA — for psilocybin in major depressive disorder, a substantially broader population than treatment-resistant depression. Usona likewise holds a Commissioner’s National Priority Voucher. The news, first reported by Psychedelic Alpha on November 2, sent CMPS down roughly 27% on competitive-pressure concerns. For the first time, there are two psilocybin applications before the FDA simultaneously — one commercial, one non-profit.
Pricing pressure: Usona is a non-profit explicitly oriented toward access rather than return. A non-profit-sponsored approval in the broader MDD indication could anchor pricing expectations far below what a commercial sponsor would set.
Indication breadth: TRD requires documented failure of multiple prior treatments. MDD does not. If Usona is approved in MDD, the eligible population is an order of magnitude larger.
Status caveat: The filing was reported by trade press; Usona declined to comment and no official press release or FDA acceptance notice has been published. Treat as credible but unconfirmed.
The first federal executive action explicitly supporting psychedelic access. Issues National Priority Vouchers for BT-designated drugs, allocates $50M via ARPA-H, directs the DEA to begin rescheduling reviews upon Phase 3 completion, and expands Right to Try applicability. FDA Commissioner Makary: approval could come “in weeks.” Joe Rogan present at signing.
Key provisions: National Priority Vouchers; $50M ARPA-H matching funds; Right to Try for psychedelics; FDA-DEA-VA data sharing; accelerated rescheduling; expanded compassionate use.
Impact on COMP360: Compass reportedly on initial Priority Voucher list. Rolling NDA Q4 2026. Approval possible late 2026 — 9–12 months earlier than pre-EO estimates.
Sources: Full EO (whitehouse.gov) · NPR · Harvard Law analysis
Psilocybin remains Schedule I under the Controlled Substances Act — and will remain so even if a product is approved, until the DEA acts separately. FDA has granted Breakthrough Therapy Designation for TRD (Compass, 2019), MDD (Cybin, 2024), and postpartum depression (2026). On July 13, 2026, the FDA finalized its psychedelic clinical trial guidance, addressing functional unblinding, design standards, and safety requirements.
The FDA held its public hearing on psychedelic therapeutics on September 14, 2026 — a four-hour hybrid session with SAMHSA, NIDA, and the VA’s Veterans Health Administration on a listening panel. Testimony centered on provider training, patient safety, access, and data standardization. Notably, the agency expressly excluded scheduling, individual product safety or efficacy, legalization, and personal or religious use from the hearing’s scope. No legal status changed as a result.
Measure 109 (2020). Service centers open since summer 2023. 20,000+ clients served to date; 5,935 in 2025 alone across 5,375 sessions, with 32.6% traveling from out of state. Adults 21+ in supervised settings. $1,000–$3,000/session; no insurance. HB 2387 (2025) allows medical professionals as facilitators. Licensed centers passed their first independent safety audit in 2026. Note: Q1 2026 was the smallest quarter on record at 952 clients — demand may be plateauing at current price points.
Prop 122 (2022). First healing center licensed April 2025. 34 licensed centers as of early 2026. Personal cultivation permitted (21+). May expand to DMT/ibogaine/mescaline by June 2026. SB 297 (2025): clemency for past convictions.
Psilocybin Behavioral Health Access and Services Act (Jan 2026). $6M allocated; three hospitals (north, central, south NJ) each receive $2M for 2-year psilocybin trials. Focus on depression and PTSD. Adults 21+ eligible. Managed by state Dept. of Health with an 11-member advisory board.
SB 219 (2025). Third state; first via legislation rather than ballot. Now accelerating — the Department of Health aims to enroll its first patients by the end of December 2026, a full year ahead of the statutory deadline, citing high interest. Producer licensing applications opened August 17, 2026. Program rules (7.35.3 NMAC) had their public hearing October 2, 2026. The 2026 budget created a $630,000 Medical Psilocybin Treatment Equity Fund for low-income and rural residents — the first equity-subsidy mechanism in any state program.
| Jurisdiction | Year | Details |
|---|---|---|
| Denver, CO | 2019 | First U.S. city — lowest law enforcement priority |
| Oakland, CA | 2019 | All entheogenic plants and fungi deprioritized |
| Santa Cruz, CA | 2020 | Deprioritized enforcement |
| Washington, D.C. | 2020 | Initiative 81 — entheogenic plants lowest priority |
| Ann Arbor / Detroit, MI | 2020–21 | Decriminalized natural psychedelics by city vote |
| Seattle, WA | 2021 | Lowest law enforcement priority |
| Somerville / Cambridge, MA | 2021–22 | Deprioritized; Easthampton, Northampton followed |
| Olympia, WA | 2024 | Plant-based hallucinogens decriminalized |
| Tacoma, WA | Jan 2025 | Natural psychedelics decriminalized |
| King County, WA | Mar 2026 | Personal psychedelic use deprioritized (Seattle metro) |
How America is changing its mind — and the forces driving that change faster than most experts predicted.
The scientists, advocates, and cultural voices who built this field — and the ones shaping where it goes next.
Lilly’s $3.8B AtaiBeckley deal closed in September. Two NDAs now sit before the FDA. And in a twist nobody modeled, a non-profit filing knocked 27% off the sector leader in a single session. The money has arrived — and so has the competition.
| Company | Ticker | Price | Mkt Cap | 52-Wk | Key Catalyst |
|---|---|---|---|---|---|
| Compass Pathways | CMPS (Nasdaq) | ~$8.61 | ~$1.22B | $4.88–$15.87 | NDA complete Nov 9; fell ~27% Nov 2 on Usona filing; Q3 loss $0.31 vs $0.39 est. |
| AtaiBeckley | delisted | $6.75 + CVR | — | — | Acquisition closed Sept 11, 2026; now a wholly owned Eli Lilly subsidiary |
| Cybin / Helus Pharma | HELP (Nasdaq) | see IR | see IR | — | HLP003 Phase 3 topline data Q4 2026; $500M secured |
| GH Research | GHRS (Nasdaq) | see IR | see IR | — | Mebufotenin Phase 3 2026; 73% Phase 2 remission; +18.9% on Lilly news |
| Usona Institute | non-profit | n/a | n/a | — | NDA filed Nov 2026 for MDD; holds Priority Voucher; not investable |
| Eli Lilly | LLY (NYSE) | see quote | ~$700B | — | Now the largest psychedelic asset owner via AtaiBeckley |
| PSIL ETF | PSIL (NYSE) | — | ETF | — | Psychedelic sector basket |
All psychedelic companies are pre-revenue. Not investment advice. Verify current prices independently.
Announced July 16 and completed September 11, 2026. Terms: $6.75/share in cash plus one contingent value right per share worth up to $2.50 on clinical and regulatory milestones — $3.8B total potential. AtaiBeckley is now a wholly owned Lilly subsidiary and has been delisted from Nasdaq. Lead asset: BPL-003 (intranasal mebufotenin, ~2-hour session window) for TRD, with Phase 2b topline data due Q4 2026. The largest psychedelic acquisition in history — and Lilly confirmed it in Q3 earnings (Oct 29).
In August 2025, AbbVie (~$300B market cap) acquired Gilgamesh Pharmaceuticals’ bretisilocin — a short-acting psilocybin analog in Phase 2 for MDD — for up to $1.2 billion. The first billion-dollar psychedelic deal by major pharma.
Compass completed its NDA submission November 9, 2026 under a Commissioner’s National Priority Voucher, setting a 30–60 day review target. But the month started badly: shares fell roughly 27% on November 2 when news broke that non-profit Usona had filed a competing NDA in the broader MDD indication. Q3 loss came in at $0.31/share against $0.39 expected. Cash was $466M at Q1 with runway into 2028. Analyst consensus remains “Moderate Buy” with a ~$23.36 target.
Usona Institute’s NDA is the single most consequential competitive event in the sector’s history, and it came from an organization with no shareholders. Usona is a non-profit pursuing the broader MDD indication and holding its own Priority Voucher. If approved, it could anchor psilocybin pricing at a level no commercial sponsor would choose — in a far larger eligible population. The 27% single-session drop in CMPS is the market pricing that risk in real time.
Cybin rebranded as Helus Pharma (Nasdaq: HELP) in December 2025 and secured a $500 million deal with High Trail Special Situations to fund HLP003 Phase 3.
Cybin/Helus corporate filings, Dec 2025
Atai Life Sciences and Beckley Psytech merged in November 2025, forming AtaiBeckley (Nasdaq: ATAI). Backed by Peter Thiel and Christian Angermayer. Advancing BPL-003 for TRD toward Phase 3.
Company announcements, Nov 2025
From the first city to decriminalize to a completed FDA application in seven years — the key moments that brought psilocybin from the fringe to the front of the regulatory queue.
The applications are filed. The review clock is running. The next 90 days will determine whether psilocybin becomes a prescription medicine in the United States — and the 18 months after that will determine whether anyone can actually get it.
Compass completed its NDA on November 9, 2026, backed by three trials that each met their primary endpoint across 1,000+ participants. Usona filed separately in major depressive disorder one week earlier. Both hold Commissioner’s National Priority Vouchers compressing review to 30–60 days. That puts a first-ever FDA decision on psilocybin somewhere between December 2026 and early 2027.
Psilocybin sponsors are pursuing drug-only approval rather than drug-plus-therapy — deliberately avoiding the structure that contributed to MDMA’s 2024 rejection. That simplifies the regulatory question but pushes the therapy-delivery problem onto states, payers, and clinics.